Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May;21(5):1181-1188.
doi: 10.1038/s41436-018-0301-4. Epub 2018 Oct 8.

Long-term follow-up in PMM2-CDG: are we ready to start treatment trials?

Peter Witters  1   2 , Tomas Honzik  3 , Eric Bauchart  4 , Ruqaiah Altassan  5   6   7 , Tiffany Pascreau  8   9 , Arnaud Bruneel  10   11 , Sandrine Vuillaumier  10 , Nathalie Seta  10   12 , Delphine Borgel  8   9 , Gert Matthijs  13 , Jaak Jaeken  14   15 , Wouter Meersseman  16   17 , David Cassiman  18 , Lonlay Pascale de  4 , Eva Morava  14   19
Affiliations
Free article

Long-term follow-up in PMM2-CDG: are we ready to start treatment trials?

Peter Witters et al. Genet Med. 2019 May.
Free article

Abstract

Purpose: PMM2-CDG is the most common congenital disorder of glycosylation (CDG), which presents with either a neurologic or multisystem phenotype. Little is known about the longitudinal evolution.

Methods: We performed data analysis on PMM2-CDG patients' clinical features according to the Nijmegen CDG severity score and laboratory data. Seventy-five patients (28 males) were followed up from 11.0 ± 6.91 years for an average of 7.4 ± 4.5 years.

Results: On a group level, there was no significant evolution in overall clinical severity. There was some improvement in mobility and communication, liver and endocrine function, and strabismus and eye movements. Educational achievement and thyroid function worsened in some patients. Overall, the current clinical function, the system-specific involvement, and the current clinical assessment remained unchanged. On follow-up there was improvement of biochemical variables with (near) normalization of activated partial thromboplastin time (aPTT), factor XI, protein C, antithrombin, thyroid stimulating hormone, and liver transaminases.

Conclusion: PMM2-CDG patients show a spontaneous biochemical improvement and stable clinical course based on the Nijmegen CDG severity score. This information is crucial for the definition of endpoints in clinical trials.

Keywords: CDG severity scale; PMM2-CDG; coagulation; liver function test; long-term follow-up.

PubMed Disclaimer

References

    1. Jaeken J, Peanne R. What is new in CDG? J Inherit Metab Dis. 2017;40:569–586. - DOI
    1. Schiff M, Roda C, Monin ML, et al. Clinical, laboratory and molecular findings and long-term follow-up data in 96 French patients with PMM2-CDG (phosphomannomutase 2-congenital disorder of glycosylation) and review of the literature. J Med Genet. 2017;54:843–851.
    1. Funke S, Gardeitchik T, Kouwenberg D, et al. Perinatal and early infantile symptoms in congenital disorders of glycosylation. Am J Med Genet A. 2013;161A:578–584. - DOI
    1. Kjaergaard S, Kristiansson B, Stibler H, et al. Failure of short-term mannose therapy of patients with carbohydrate-deficient glycoprotein syndrome type 1A. Acta Paediatr. 1998;87:884–888. - DOI
    1. Mayatepek E, Kohlmuller D. Mannose supplementation in carbohydrate-deficient glycoprotein syndrome type I and phosphomannomutase deficiency. Eur J Pediatr. 1998;157:605–606. - DOI

Publication types

Substances

Supplementary concepts

LinkOut - more resources